Report of Foreign Issuer (6-k)
September 16 2019 - 4:19PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of September 2019
Commission File Number: 001-37452
CELYAD SA
(Translation
of registrants name into English)
Rue Edouard
Belin 2
1435 Mont-Saint-Guibert, Belgium
(Address of principal executive offices)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Celyad SA
On September 16, 2019, Celyad SA (the Company) issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is
incorporated by reference herein.
The information contained in this Current Report on Form 6-K, including
Exhibit 99.1, is hereby incorporated by reference into the Companys Registration Statements on Forms F-3 (File No. 333-220285) and S-8 (File No. 333-220737).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CELYAD SA
|
|
|
|
|
Date: September 16, 2019
|
|
|
|
By:
|
|
/s/ Filippo Petti
|
|
|
|
|
|
|
Filippo Petti
Chief Executive Officer and
Financial Officer
|
Celyad Oncology (NASDAQ:CYAD)
Historical Stock Chart
From Apr 2024 to May 2024
Celyad Oncology (NASDAQ:CYAD)
Historical Stock Chart
From May 2023 to May 2024